The cost of life-saving diabetes drug Ozempic has become a symbol of global health inequality, with Canadians paying a fraction of the price faced by Americans. As the UK watches on, the NHS pricing model is under renewed pressure to deliver fair access.
Ozempic, manufactured by Novo Nordisk, is a GLP-1 receptor agonist used to manage type 2 diabetes. In the United States, a month's supply can cost upwards of $900, while in Canada, the same drug is available for around $200. The discrepancy stems from vastly different healthcare systems: Canada's single-payer model negotiates bulk discounts, whereas the US allows drugmakers to set prices virtually unchecked.
For British patients, the situation is more complex. The NHS, through the National Institute for Health and Care Excellence (NICE), has approved Ozempic but only for specific patient groups, reflecting a cost-effectiveness threshold. However, recent supply shortages and rising demand have exposed cracks in the system. Some UK patients report being unable to access the drug due to rationing, while others face delays as the NHS renegotiates contracts.
"This isn't just about Ozempic," says Dr. Helen McCarthy, a health economist at the University of Manchester. "It's about the principles of a public health service. If Canadians can secure lower prices through collective bargaining, why can't we?"
The NHS currently uses a voluntary scheme with the pharmaceutical industry, but critics argue it lacks teeth. The government's recent move to cap drug spending at 2% per year may do little to address specific inequities. Meanwhile, patient groups warn that the UK risks falling behind in access to innovative treatments.
For working-class families in the North, where diabetes rates are higher and wages are stagnant, the cost of medication can be a daily struggle. "I've had to choose between my insulin and putting food on the table," says Margaret, a 58-year-old from Sheffield who asked not to use her full name. "It's a disgrace that Canadians get a better deal."
Economists point to the broader implications. "Drug pricing isn't just a health issue; it's an economic one," says Professor James O'Neill at the London School of Economics. "When people can't afford their medication, they end up in A&E, costing the system more. The savings from lower drug prices could be redirected to frontline services."
As the US explores price controls through the Inflation Reduction Act, and Canada maintains its negotiation power, the UK must decide whether to strengthen its own bargaining position. The current system, which relies on voluntary agreements and rebates, may no longer be fit for purpose.
In the meantime, patients like Margaret are left to pray for change. "The NHS is supposed to be the best in the world," she says. "But when it comes to actually getting the drugs you need, it feels like we're being left behind."
